Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EC-203
- Development stage
- Preclinical
- Lead developer
- ExoCan Healthcare Technologies
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
EC-203 is a therapeutic candidate currently in development by ExoCan Healthcare Technologies, primarily targeting applications within regenerative medicine. While specific molecular details and mechanisms of action remain undisclosed, the drug is part of ExoCan's pipeline which leverages exosome-based technologies. The company specializes in the isolation and engineering of extracellular vesicles (exosomes) to deliver therapeutic payloads or signaling molecules to specific tissues. EC-203 is intended to utilize these vesicles to promote tissue repair and regeneration, addressing unmet needs in degenerative conditions.
Beyond the preview
Go deeper on EC-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EC-203.